Axonics submits interim data to FDA for sacral neuromodulation system

09:14 EST 4 Jan 2019 | Compelo Medical Devices

Axonics stated that its ARTISAN-SNM study is a 129-patient single-arm, multi-center, unblinded pivotal clinical study, which has been approved by the FDA under Investigational Device Exemption (IDE) to

The post Axonics submits interim data to FDA for sacral neuromodulation system appeared first on Compelo Medical Devices.

Original Article: Axonics submits interim data to FDA for sacral neuromodulation system

More From BioPortfolio on "Axonics submits interim data to FDA for sacral neuromodulation system"